Literature DB >> 12203188

Exogenous cushing syndrome mimicking human immunodeficiency virus lipodystrophy.

Samir K Gupta1, Michael P Dubé.   

Abstract

A 45-year-old man infected with human immunodeficiency virus (HIV) developed abnormal fat accumulations that initially were believed to be caused by HIV lipodystrophy. Further clinical evaluation revealed, however, that the patient had developed exogenous Cushing syndrome, which presumably was caused by the inhibition of CYP3A4's metabolism of inhaled fluticasone by the protease inhibitor ritonavir. Clinicians should be aware that clinical clues may indicate conditions other than lipodystrophy that may cause abnormal fat accumulation and that fluticasone should be cautiously administered to patients who are receiving ritonavir.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203188     DOI: 10.1086/342562

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

Review 1.  Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature.

Authors:  Therdpong Tempark; Voraluk Phatarakijnirund; Susheera Chatproedprai; Suttipong Watcharasindhu; Vichit Supornsilchai; Siriwan Wananukul
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

2.  Iatrogenic Cushing's syndrome and osteoporosis due to an interaction between fluticasone and ritonavir.

Authors:  Luísa Azevedo; Hugo Pêgo; Teresa Souto Moura; Isabel Germano
Journal:  BMJ Case Rep       Date:  2015-10-29

Review 3.  Molecular Probes, Chemosensors, and Nanosensors for Optical Detection of Biorelevant Molecules and Ions in Aqueous Media and Biofluids.

Authors:  Joana Krämer; Rui Kang; Laura M Grimm; Luisa De Cola; Pierre Picchetti; Frank Biedermann
Journal:  Chem Rev       Date:  2022-01-07       Impact factor: 60.622

4.  Iatrogenic Cushing's syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir.

Authors:  J C Yombi; D Maiter; L Belkhir; A Nzeusseu; B Vandercam
Journal:  Clin Rheumatol       Date:  2008-10-01       Impact factor: 2.980

Review 5.  Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management.

Authors:  P Saberi; T Phengrasamy; D P Nguyen
Journal:  HIV Med       Date:  2013-04-16       Impact factor: 3.180

6.  Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.

Authors:  Kristin H Busse; Elizabeth Formentini; Raul M Alfaro; Joseph A Kovacs; Scott R Penzak
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-15       Impact factor: 3.731

7.  Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review.

Authors:  Melpomeni Peppa; Maria Krania; Sotirios A Raptis
Journal:  Integr Blood Press Control       Date:  2011-03-03

8.  Inhalational Steroids and Iatrogenic Cushing's Syndrome.

Authors:  Raveendran A V
Journal:  Open Respir Med J       Date:  2014-01-31

9.  Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone.

Authors:  Narendranath Epperla; Fergus McKiernan
Journal:  Springerplus       Date:  2015-08-27

10.  Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.

Authors:  R Chris Rathbun; Michelle D Liedtke
Journal:  Pharmaceutics       Date:  2011-10-21       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.